EGFR Targeted Liposomal PROTAC Assisted With Epigenetic Regulation as an Efficient Strategy for Osimertinib‐Resistant Lung Cancer Therapy
Authors:
Open Access
- 21 August 2025
- journal article
- Published by Wiley in Advanced Science
- Vol. 12 (43) , e10197
Abstract
Osimertinib resistance is a global problem for NSCLC patients mediated by new EGFR mutations or bypass mechanisms. Proteolysis targeting chimeras (PROTACs) have been utilized to overcome drug resistance by degrading mutant EGFR, but most are restricted to their poor cell permeability and insufficient tumor‐targeting ability. Meanwhile, these PROTACs has little effect on bypass resistance mechanisms. In this study, a versatile split‐and‐mix liposomal PROTAC is developed for EGFR degradation based on liposome self‐assembly containing DSPE‐PEG2000‐E3 ligand and DSPE‐PEG2000‐EGFR ligand. Unlike traditional PROTACs, this platform can achieve efficient EGFR degradation via both E3‐dependent mechanisms and the lysosome‐autophagy pathway. To further increase its sensitivity to osimertinib‐resistant lung cancer cells, the liposomal PROTAC is encapsulated with class I HDAC inhibitor MS‐275 (GM‐protac) by both blocking the EGFR‐dependent pathways and bypass resistant mechanisms. GM‐protac shows selective toxicity on gefitinib‐resistant and osimertinib‐resistant lung cancer cells. The mechanism analysis reveals that GM‐protac can influence the BIM‐associated apoptosis pathway, c‐Met, PD‐L1, HER‐2, NF‐κB or PI3K‐AKT signaling pathway, etc. Meanwhile, they displayed obvious tumor inhibition with negligible toxicity in both osimertinib and gefitinib‐resistant lung cancer animal models. This work provides an alternative option for osimertinib‐resistant lung cancer therapy.Keywords
Funding Information
- National Natural Science Foundation of China (82474007)
- National Natural Science Foundation of China (82274026)
- National Natural Science Foundation of China (22007033)
This publication has 61 references indexed in Scilit:
- Management of locally advanced non‐small cell lung cancer: State of the art and future directionsCancer Communications, 2023
- BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk AxisAdvanced Science, 2023
- Acquired resistance mechanisms to osimertinib: The constant battleCancer Treatment Reviews, 2023
- Non‐small cell lung cancer in ChinaCancer Communications, 2022
- Recent advances in the development of EGFR degraders: PROTACs and LYTACsEuropean Journal of Medicinal Chemistry, 2022
- Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast CancerAngewandte Chemie International Edition, 2021
- Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systemsEuropean Journal of Medicinal Chemistry, 2021
- Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFRT790M mutant cell linesEuropean Journal of Medicinal Chemistry, 2021
- Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challengesEuropean Journal of Medicinal Chemistry, 2021
- Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspectiveDrug Discovery Today, 2020